hidradenitis/headache

Eight patients, 7 with hidradenitis suppurativa and 1 with chronic recurrent staphylococcal abscess, all of whom failed to respond to antibiotic therapy, conservative therapeutic measures, and surgery, were experimentally placed on Staphage Lysate. Treatment after appropriate skin testing consisted

BACKGROUND Hidradenitis suppurativa is a chronic inflammatory disease characterized by significant morbidity. Current medical therapies are usually only minimally effective. OBJECTIVE To assess the efficacy and safety of infliximab monotherapy for the treatment of severe extensive refractory forms

An inappropriate immunologic response has been suggested to play a role in the pathogenesis of hidradenitis suppurativa (HS). Adalimumab was the first TNF-α inhibitor approved for moderate to severe HS. We report on a case of HS (Hurley stage 2) in a 39-year-old man, who had received fusidic acid

BACKGROUND Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited. OBJECTIVE To evaluate the efficacy and short-term safety of apremilast in patients with moderate HS. METHODS A total of 20 patients with moderate HS were randomized in a 3:1 ratio to receive blinded